<p>Geron Corporation published a document on the IMproveMF Phase 1b clinical study evaluating imetelstat in combination with ruxolitinib for patients with myelofibrosis. The document includes information on study endpoints, enrollment status, site locations, and references to related clinical research. The full document can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief on December 08, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

GERN

<p>Geron Corporation has released results from its IMproveMF Phase 1b trial, studying imetelstat with ruxolitinib for myelofibrosis treatment. The document details study endpoints, enrollment status, and site locations. This AI-generated brief is informational and not financial advice. Geron published the original content on December 8, 2025.</p>

Geron Corporation Releases Phase 1b Trial Results on Imetelstat Plus Ruxolitinib for Myelofibrosis